Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Selective Antigen Specific dTβRII-expressing T Cells and B7-H3 CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

NCT07172958 is registered in ClinicalTrials.gov with Children's National Research Institute as lead sponsor.

NCT NCT07172958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07172958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Selective Antigen Specific dTβRII-expressing T Cells and B7-H3 CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Lead sponsor
Children's National Research Institute
Phase
Phase 1
Overall status
Recruiting
Start date
January 27, 2026
Completion date
December 31, 2044
Enrollment
18 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma, neuroblastoma, rhabdomyosarcoma, wilms tumor